Granted Patent
B2
US 12,473,371 · App. 18/312,897 · Granted Nov 18, 2025
Anti-OPG antibodies
Inventors:
Joana De Abreu Carvalho (Cambridge, GB); Steve Holmes (Cambridge, GB); Allan LAwrie (South Yorkshire, GB)
Assignee:
KYMAB LIMITED
C07K16/2878A61K39/3955A61K45/06A61P9/12A61K2039/505C07K2317/21C07K2317/31C07K2317/52C07K2317/565C07K2317/732C07K2317/734C07K2317/76C07K2317/92C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
Claims (8)
1 . A method of treating a disease or disorder in a patient in need thereof, comprising administering to the patient an effective amount of an antibody or antigen binding fragment thereof that specifically binds to human osteoprotegerin (hOPG), thereby treating the disease or disorder in the patient; wherein the disease or disorder is systemic hypertension, resistant hypertension, pulmonary hypertension (PH), or pulmonary arterial hypertension (PAH); and
wherein the antibody or antigen binding fragment thereof that specifically binds to human osteoprotegerin (hOPG) comprises a heavy chain variable region (VH) and a light chain variable region (VL), comprising:
(a) the CDRH1 amino acid sequence of SEQ ID NO: 46 or SEQ ID NO: 49, the CDRH2 amino acid sequence of SEQ ID NO: 47 or SEQ ID NO: 50, the CDRH3 amino acid sequence of SEQ ID NO: 48 or SEQ ID NO: 51; and
(b) the CDRL1 amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 59, the CDRL2 amino acid sequence of SEQ ID NO: 57 or SEQ ID NO: 60, and the CDRL3 amino acid sequence of SEQ ID NO: 58 or SEQ ID NO: 61.
2 . The method of claim 1 , wherein the VH comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 52, and wherein the VL comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 62.
3 . The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises:
(i) a heavy chain comprising the VH and a heavy chain constant region (CH), the heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 54; and
(ii) a light chain comprising the VL and a light chain constant region (CL), the light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 64.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 16, 2025
From: DE ABREU CARVALHO, JOANA; HOLMES, STEVE; LAWRIE, ALLAN
To: KYMAB LIMITED
Reel/Frame 072265/0124 →
Priority Claims (2)
GB 1701416
· Jan 27, 2017
· national
GB 1717006
· Oct 16, 2017
· national
Continuity (2)
Division
16480903
References Cited (124)
US 4675187A
· Konishi et al.
· 1987
[cited by applicant]
US 4880078A
· Inoue et al.
· 1989
[cited by applicant]
US 5290540A
· Prince et al.
· 1994
[cited by applicant]
US 5843678A
· Boyle
· 1998
[cited by applicant]
US 5855913A
· Hanes et al.
· 1999
[cited by applicant]
US 5874064A
· Edwards et al.
· 1999
[cited by applicant]
US 5934272A
· Lloyd et al.
· 1999
[cited by applicant]
US 5985309A
· Edwards et al.
· 1999
[cited by applicant]
US 5985320A
· Edwards et al.
· 1999
[cited by applicant]
US 6015938A
· Boyle et al.
· 2000
[cited by applicant]
US 6019968A
· Platz et al.
· 2000
[cited by applicant]
US 6087555A
· Dunstan et al.
· 2000
[cited by applicant]
US 6284728B1
· Boyle et al.
· 2001
[cited by applicant]
US 6284740B1
· Boyle et al.
· 2001
[cited by applicant]
US 6316408B1
· Boyle
· 2001
[cited by applicant]
US 6613544B1
· Boyle et al.
· 2003
[cited by applicant]
US 6919434B1
· Goto et al.
· 2005
[cited by applicant]
US 9334327B2
· Lawrie et al.
· 2016
[cited by applicant]
US 20030207827A1
· Boyle et al.
· 2003
[cited by applicant]
US 20110311995A1
· Mouthon et al.
· 2011
[cited by applicant]
US 20170202918A1
· Yung et al.
· 2017
[cited by applicant]
US 20180008672A1
· Chalothorn et al.
· 2018
[cited by applicant]
US 20180057580A1
· Chalothorn et al.
· 2018
[cited by applicant]
WO WO1992019244A2
· 1992
[cited by applicant]
WO WO1997023614A1
· 1996
[cited by applicant]
WO WO1997032572A2
· 1997
[cited by applicant]
WO WO1997044013A1
· 1997
[cited by applicant]
WO WO1998031346A1
· 1998
[cited by applicant]
WO WO1998046751A1
· 1998
[cited by applicant]
WO WO1999066903A2
· 1999
[cited by applicant]
WO WO2001083560A1
· 2001
[cited by applicant]
WO WO2003037913A2
· 2003
[cited by applicant]
WO WO2003038043A2
· 2003
[cited by applicant]
WO WO2008003103A2
· 2008
[cited by applicant]
WO WO2011004192A1
· 2011
[cited by applicant]
WO WO2011158009A1
· 2011
[cited by applicant]
WO WO2013061098A2
· 2013
[cited by applicant]
WO WO2013064810A1
· 2013
[cited by applicant]
WO WO2014042981A2
· 2014
[cited by applicant]
WO WO2014174254A2
· 2014
[cited by applicant]
WO WO2015036737A1
· 2015
[cited by applicant]
WO WO2015103072A1
· 2015
[cited by applicant]
WO WO2018138297A1
· 2018
[cited by applicant]
WO WO2021158413A1
· 2021
[cited by applicant]
Lawrie et al. Osteoprotegerin blockage prevents and reverses experimental pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine, (2012) vol. 185, Supp. Meeting Abstracts. ABSTRACT N…
[cited by examiner]
Al Qaraghuli et al., “Antibody-protein binding and conformational changes: identifying allosteric signaling pathways to engineer a better effector response”, Nature Scientific Reports, 2020, 10: 13969.
[cited by applicant]
Alvarez et al., “Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates”. Arthritis Rheum., 2003, vol. 48, No. 3, pp. 824-8280.
[cited by applicant]
Arnold et al., “A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension”, Nat Commun., Nov. 15, 2019, 10: 5183.
[cited by applicant]
Baud'huin et al., “Osteoprotegerin: Multiple partners for multiple functions”, Cytokine & Growth Factor Reviews, 2013, vol. 24, pp. 401-409.
[cited by applicant]
Bharti et al., “Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism”, Jo…
[cited by applicant]
Bhattacharya et al., “Impact of genetic variation on three dimensional structure and function of proteins”, PLOS One, Mar. 2017, 12(3): e0171355, pp. 1-22.
[cited by applicant]
Bucay et al., “Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,” Genes & Development 12:1260-1268 (1998).
[cited by applicant]
Caidahl et al., “Osteoprotegerin: a biomarker with many faces”, Arterioscler. Thromb. Vasc. Biol., 2010, vol. 30, No. 9, pp. 1684-1686.
[cited by applicant]
Chemla, “New formula for predicting mean pulmonary artery pressure (mPAP) using systolic pulmonary artery pressure”, Chest, 2004, vol. 126, pp. 1313-1317.
[cited by applicant]
Chen et al., “Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss”, PNAS, Apr. 22, 2014, 111(16): 6040-6045.
[cited by applicant]
Chen et al., “Arthritogenic alphaviruses: new insights into arthritis and bone pathology”, Trends in Microbiology, Jan. 2015, vol. 23, No. 1, pp. 35-43.
[cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”, Journal of Molecular Biology, Aug. 20, 1987, 196(4): 901-917.
[cited by applicant]
Condliffe et al., “Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension,” Pulmonary Circulation 2(1):21-27 (2012).
[cited by applicant]
Dall'Acqua, et al., “Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)”, Journal of Biology Chemistry, vol. 281, No. 33, pp. 23514-23524, Aug. 18, 2006.
[cited by applicant]
Dawson et al., “TRAIL Deficient Mice Are Protected from Sugen/Hypoxia Induced Pulmonary Arterial Hypertension,” Diseases 2:260-273 (2014).
[cited by applicant]
De Ciriza et al., “Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification”, Clin Biochem., Dec. 2014, 47(18): 272-278.
[cited by applicant]
De Ciriza et al., “Osteoprotegerin in Cardiometabolic Disorders”, Int J Endocrinol., 2015, 2015: 564934.
[cited by applicant]
Digiammarino et al., “Design and generation of DVD-Ig™ molecules for dual-specific targeting”, Methods in Molecular Biology, Jan. 1, 2012, 899: 145-156.
[cited by applicant]
Edwards et al., “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein”, BLyS. Journal of Molecular Biology, 2003, 334: 103-118.
[cited by applicant]
Emery et al., “Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL,” Journal of Biological Chemistry 273(23):14363-14367 (1998).
[cited by applicant]
Goel et al., “Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response”, J. Immunol., 2004, 173: 7358-7367.
[cited by applicant]
GÜL et al., “Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer”, Cancer Research, Dec. 1, 2015, 75(23): 5008-5013.
[cited by applicant]
Hameed et al., “Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension,” Journal of Experimental Medicine 209(11):1919-1935 (2012).
[cited by applicant]
Hoeper et al., “Definitions and Diagnosis of Pulmonary Hypertension”, Journal of the American College of Cardiology, Dec. 16, 2013, 62(25).
[cited by applicant]
Hofbauer et al., “Osteoprotegerin: a link between osteoporosis and arterial calcification?”, The Lancet, Jul. 28, 2001, 358(9278): 257-259.
[cited by applicant]
Holen et al., “Role of osteoprotegerin (OPG) in cancer,” Clinical Science 110: 279-291 (2006).
[cited by applicant]
Humbert et al., “Treatment of Pulmonary Arterial Hypertension,” New England Journal of Medicine 351(14):1425-1436 (2014).
[cited by applicant]
Hurdman et al., “ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre”, European Respiratory Journal, 2012, 39: 945-955.
[cited by applicant]
Idusogie et al., Engineered antibodies with increased activity to recruit complement. J. Immunol., 2001, 166: 2571-2575.
[cited by applicant]
Igawa et al., “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization”, Nature Biotechnology, 2010, vol. 24, No. 11, pp. 1203-1207.
[cited by applicant]
International Preliminary Report on Patentability for PCT International Patent Application No. PCT/EP2018/052017, mailed Mar. 29, 2018.
[cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2018/052017, mailed Jul. 30, 2019.
[cited by applicant]
Jia, “Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin avp3/FAK/AKT Pathway Suppression”, Circulation: Cardiovascular Genetics, 2017, vol. 10, p. e001591.
[cited by applicant]
Justice et al., “Using the mouse to model human disease: increasing validity and reproducibility”, Disease, Models & Mechanisms, 2016, 9: 101-103.
[cited by applicant]
Kabat et al., “Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains”, Ann. NY Acad. Sci., 1971, vol. 190, pp. 382-391.
[cited by applicant]
Khan et al., “Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies”, J. Immunol., 2014, 192: 5398-5405.
[cited by applicant]
Kilpatrick et al., “Rapid Development of Affinity Matured Monoclonal Antibodies Using RIMMS”, Hybridoma, Aug. 1997, 16(4): 381-389.
[cited by applicant]
Kook et al., “Mechanical Force Inhibits Osteoclastogenic Potential of Human Periodontal Ligament Fibroblasts Through OPG Production and ERK-Mediated Signaling,” Journal of Cellular Biochemistry 106:1010-1019 (2009).
[cited by applicant]
Lane et al., “Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis”, Journal of Ovarian Research, Nov. 23, 2013, 6(1): 82.
[cited by applicant]
Lawrie et al., “Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension”, The American Journal of Pathology, Jan. 1, 2008, 172(1): 256-264.
[cited by applicant]
Lawrie et al., “Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension,” American Journal of Pathology 172(1):256-264 (2008).
[cited by applicant]
Lazar et al., Engineered antibody Fc variants with enhanced effector function, Proc. Natl. Acad. Sci. U.S.A., Mar. 14, 2006; 103(11): 4005-4010.
[cited by applicant]
Lee et al., Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery, Nature Biotechnology, Mar. 16, 2014; 32: 356-363.
[cited by applicant]
Lefranc et al., “Unique database numbering system for immunogenetic analysis”, Immunology Today, Nov. 1, 1997, 18(11): 509.
[cited by applicant]
Lloyd et al., “Modelling the human immune response: performance of a 10(11) human antibody repertoire against a broad panel of therapeutically relevant antigens”, Protein Engineering, Eng. Design & Selection, 2009, 22(3…
[cited by applicant]
Malyankar et al., “Osteoprotegerin Is an alpha vbeta 3-induced, NF-kappa ß-dependent Survival Factor for Endothelial Cells”, Journal of Biological Chemistry, 2000, vol. 275, pp. 20959-20962.
[cited by applicant]
Mathis, “Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer”, Clinical Chemistry, 1995, vol. 41, No. 9, pp. 1391-1397.
[cited by applicant]
McMurtry et al., “Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension”, The Journal of Clinical Investigation, Jun. 2005, 115(6): 1479-1491.
[cited by applicant]
Moran et al., “Osteoprotegerin deficiency limits angiotensin II-induced aortic dilation and rupture in the apolipoprotein E-knockout mouse,” Arteriosclerosis Thrombosis and Vascular Biology 34(12):2609-2616 (2014).
[cited by applicant]
Morel, “Mouse models of human autoimmune diseases: Essential tools that require proper controls”, PLOS Biology, Aug. 2004, 2(8): 1061-1064.
[cited by applicant]
Morrell et al., “Cellular and molecular basis of pulmonary arterial hypertension”, J. Am. Coll. Cardiol., Jun. 30, 2009, 54(1 Suppl): S20-S31.
[cited by applicant]
Natsume et al., 2008, Engineered Antibodies of lgG1/lgG3 Mixed Isotype with Enhanced Cytotoxic Activities, Cancer Res., 68: 3863-3872.
[cited by applicant]
Natsume et al., Improving effector functions of antibodies for cancer treatment : Enhancing ADCC and CDC, 2009, Drug Des. Devel. Ther., 3: 7-16.
[cited by applicant]
Neiderfellner et al., “Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies”, Blood, Jul. 14, 2011, 118(2): 358-367.
[cited by applicant]
NHS, Treatment—Pulmonary Hypertension, Jan. 23, 2020, obtained from url: https://www.nhs.uk/conditions/pulmonary-hypertension/treatment/.
[cited by applicant]
O'Regan et al., “Marked elevation in plasma osteoprotegerin constitutes an early and consistent feature of cerebral malaria”, Thrombosis and Haemostasis, 2016, vol. 115, No. 4, pp. 773-780.
[cited by applicant]
Poosarla et al., “Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity”, Biotechn. Bioeng., 2017, 114(6): 1331-1342.
[cited by applicant]
Pulmonary Heart Association, “Scientists Hope to Expand Pre-Clinical Studies of Antibody to Protein Increased in PAH”, Nov. 21, 2019, obtained from url: https://phassociation.org/scientists-hope-to-expand-pre-clinical-s…
[cited by applicant]
Rabia, et al., “Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility”, Biochemical Engineering Journal, 2018, 137: 365-374.
[cited by applicant]
Rothman et al., “MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension”, J. Clin. Invest, 2016, vol. 126, No. 7, pp. 2495-1508.
[cited by applicant]
Said, “Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene”, Circulation, 2007, 115: 1260-1268.
[cited by applicant]
Schermuly et al., “Mechanisms of disease: Pulmonary arterial hypertension”, Nature Reviews Cardiology, Aug. 1, 2011, 8(8): 443-455.
[cited by applicant]
Shields et al., High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma Rill, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R., J. Biol. Chem., Mar.…
[cited by applicant]
Simonet et al., “Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density,” Cell 89:309-319 (1997).
[cited by applicant]
St{tilde under (e)}pień et al., “Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals”, Clin Biochem., Jul. 2011, 44(10-11): 826-831.
[cited by applicant]
Suckau et al., “Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping”, Biochemistry Naser, J. Immunol., Dec. 1, 1990, 87(141): 9848-98…
[cited by applicant]
Tokuriki et al., “Stability effects of mutations and protein evolvability”, Current Opinion in Structural Biology, 2009, 19: 596-604.
[cited by applicant]
Turkbeyler et al., “Prolidase Could Act as a Diagnosis and Treatment Mediator in Lung Fibrosis”, Inflammation, Oct. 2012, 35(5): 1747-1752.
[cited by applicant]
Wakabayashi et al., “Prevention of metastasis by a polyamine synthesis inhibitor in an animal bone metastasis model”, Oncology, 2000, 59: 75-80.
[cited by applicant]
Wong, “Apoptosis in cancer: from pathogenesis to treatment”, Journal of Experimental & Clinical Cancer Research, 2011, 30: 87.
[cited by applicant]
Wu, “Receptor-mediated in vitro gene transformation by a soluble DNA carrier system”, Journal of Biol. Chem., 1987, vol. 262, No. 10, pp. 4429-4432.
[cited by applicant]
Zhou, “Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function”, Biotechnol. Bioeng., Feb. 15, 2008, vol. 99, No. 3, pp. 652-665.
[cited by applicant]
Tuder et al., “Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension”, Journal of the American College of Cardiology, Dec. 2013, 62(25_Suppl), D4-D12.
[cited by applicant]